Medicines design, development of biologics and delivery, with the aim to attain the precise target sites.
This theme comprises experts in the broad fields of drug design and delivery with an overall aim to facilitate the creation of better medicines. The specific goals are: (1) to generate new chemical entities as potential therapeutics and as molecular probes to aid in fundamental research, and (2) to improve formulations in order to increase the rate and extent of drug absorption at its site of administration (the so-called bioavailability of the drug) and (3) improve delivery and development of so-called “biologics” such as proteins, vaccines, antibodies and antibody-drug conjugates). The molecular events taking place at the interface between the formulation delivering the drug, and the mechanism by which it is absorbed and then interacts with its biological target, are complex and depend on many factors. Indeed, the development of biologics as medicines presents a different set of biological and biophysical problems to overcome compared to small chemical entities.
Presently, there are few reliable, simple, experimental or theoretical tools that can predict how well a medicine might work. As a result, the pharmaceutical industry is often obliged to undertake expensive and lengthy animal or clinical studies to answer this question. Our research addresses these challenges by developing a suite of experimental methods and predictive models to direct the efficient and rational design and optimisation of high-performance drugs and drug products. In essence, therefore, this drug development initiative complements the focus of the iCTI strategy by enabling new drug discovery and its eventual translation into novel and effective therapies for patient benefit.